Background: The -945C/G polymorphism of the connective tissue growth factor (CTGF) has been associated with systemic sclerosis, however, results were conflicted. The aim of this study was to validate the evidence for the CTGF -945C/G polymorphism and systemic sclerosis risk.
Methods: Electronic search of PubMed was conducted to select studies. Case-control studies containing available genotype frequencies of -945C/G were chosen, and odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of this association.
Results: Six published case-control studies including 3335 cases and 3589 controls were identified. The overall results suggested that the variant genotypes were not associated with the systemic sclerosis risk (OR=0.947, 95% CI: 0.792-1.132, p=0.55). The stratified analysis in Caucasian (OR=1.002, 95% CI: 0.837-1.2, p=0.788) did not suggest an association either. However, analysis in Asian (OR=0.632, 95% CI: 0.459-0.869, p=0.005) showed that CC/CG genotype greatly decreased the susceptibility of systemic sclerosis in a dominant model. Asymmetric funnel plot, the Egger's test (p=0.292), and the Begg's test (p=0.593) were all suggestive of the lack of publication bias.
Conclusion: This meta-analysis supports that CC/CG genotype greatly decreased the susceptibility of systemic sclerosis in Asian. Due to the limited samples in subpopulations, further prospective studies with larger number of participants worldwide are needed to examine the association between the CTGF -945C/G polymorphism and systemic sclerosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gene.2012.07.061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study.
Clin Rheumatol
January 2025
Rheumatology Unit, Scleroderma Unit, University Hospital of Modena, Via del Pozzo, 71-41125, Modena, Italy.
The aims of this study were to investigate the prevalence of cryofibrinogenemia in a cohort of patients with systemic sclerosis (SSc) regardless of clinical manifestations, who were admitted to our hospital and determine the associations among CF positivity, disease features and ongoing therapies. This was a monocentric and retrospective study. The inclusion criteria were a diagnosis of SSc (according to the ACR/EULAR 2013 classification criteria), regular administration of i.
View Article and Find Full Text PDFConsensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.
Neurol Clin Pract
April 2025
Department of Neurology, New York University Langone Health.
Background And Objectives: Neurosarcoidosis poses a diagnostic and management challenge due to its rarity, phenotypic variability, and lack of randomized controlled studies to guide treatment selection. Recommendations for management based on expert opinion are useful in clinical practice and provide a framework for designing prospective studies.
Methods: In this Delphi survey study, specialists with experience in managing patients with neurosarcoidosis were invited to anonymously complete 2 surveys about key elements of evaluation, diagnosis, treatment, monitoring, and long-term management of neurosarcoidosis.
A Scleroderma and Raynaud's UK (SRUK) national survey to explore rheumatologists' awareness, approaches to diagnosis and management and training needs within systemic sclerosis.
Rheumatol Adv Pract
December 2024
Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Objectives: Patients' outcomes and experiences can be affected by rheumatologist knowledge and awareness of systemic sclerosis (SSc). Our survey, directed at UK-based rheumatologists, aimed to expand our understanding of the above points along with their ability to keep up to date with guidelines defining best practice.
Methods: Rheumatologists were invited to participate in an online survey, with the results analysed and presented descriptively and graphically by SRUK.
Immunosuppressive therapy to treat newly diagnosed primary heart involvement in patients with systemic sclerosis: An Italian cardiac magnetic resonance based study.
Semin Arthritis Rheum
January 2025
Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Background: Primary heart involvement (pHI) is frequent in systemic sclerosis (SSc), and is associated with a poor prognosis. Therapeutic strategies to treat SSc-pHI are not yet defined.
Objectives: To evaluate the efficacy of immunosuppressive therapy on cardiac magnetic resonance (CMR) features in patients with CMR-proven SSc-pHI.
Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis.
J Dermatol Sci
January 2025
Biosciences Department, Durham University, Durham, United Kingdom. Electronic address:
Background: Systemic Sclerosis (SSc) is an idiopathic rheumatic inflammatory disease that is characterised by inflammation and skin fibrosis. Type I interferon is significantly elevated in the disease.
Objective: The objective of this study is to determine the role of the TCA cycle metabolite fumarate in SSc.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!